Tag: clinical guidelines

—

by

Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. The 30-second version What. The causal case for lipoprotein(a), Lp(a), as a driver of atherosclerotic cardiovascular disease is one of the strongest genetic cases in cardiology — Mendelian randomization…

How far does definition-setting power reach? The four-layer chain from CKM taxonomy to guideline, ICD code and drug label

—

by

Evidence-first notes on bioscience and medical affairs, at the edge of the clinic and the market. Information only — not investment advice, not medical advice. The 30-second version What. This part traces, layer by layer, how US definition-setting power moves down a four-stage chain — definition (taxonomy) → guideline (COR/LOE) → ICD code / reimbursement…

The drug is the battleground — what GLP-1, SGLT2i and resmetirom labels reveal about who really owns the CKM/SMD taxonomy

—

by

Evidence-first notes on bioscience and medical affairs, at the edge of the clinic and the market. Information only — not investment advice, not medical advice. The 30-second version What. Reading the actual approved labels of the CKM/SMD-defining drug classes — GLP-1 (semaglutide, tirzepatide), SGLT2i (empagliflozin, dapagliflozin), the first MASH drug resmetirom, and finerenone — against…

The European/global axis annexes the liver — how SMD and MASLD attack the missing organ in the US CKM standard, and why the glue is the drug, not the taxonomy

—

by

Evidence-first notes on bioscience and medical affairs, at the edge of the clinic and the market. Information only — not investment advice, not medical advice. The 30-second version What. Part 1 identified the largest gap in the US CKM standard as the absence of the liver. The European/global axis attacks exactly that gap: the EAS…

The asymmetry in the US cardiovascular-kidney-metabolic standard — widen the diagnosis, narrow the drug threshold

Jul 11, 2026

—

by